|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sweeney CJ, Chen YH, Carducci M, Liu G,
Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et
al: Chemohormonal therapy in metastatic hormone-sensitive prostate
cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fizazi K, Tran N, Fein L, Matsubara N,
Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S,
Protheroe A, et al: Abiraterone acetate plus prednisone in patients
with newly diagnosed high-risk metastatic castration-sensitive
prostate cancer (LATITUDE): Final overall survival analysis of a
randomised, double-blind, phase 3 trial. Lancet Oncol. 20:686–700.
2019. View Article : Google Scholar
|
|
4
|
Armstrong AJ, Szmulewitz RZ, Petrylak DP,
Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi
T, Shore ND, et al: ARCHES: A randomized, phase III study of
androgen deprivation therapy with enzalutamide or placebo in men
with metastatic hormone-sensitive prostate cancer. J Clin Oncol.
37:2974–2986. 2019. View Article : Google Scholar
|
|
5
|
Chi KN, Chowdhury S, Bjartell A, Chung BH,
Pereira de Santana Gomes AJ, Given R, Juárez A, Merseburger AS,
Özgüroğlu M, Uemura H, et al: Apalutamide in patients with
metastatic castration-sensitive prostate cancer: Final survival
analysis of the randomized, double-blind, phase III TITAN study. J
Clin Oncol. 39:2294–2303. 2021. View Article : Google Scholar
|
|
6
|
Smith MR, Hussain M, Saad F, Fizazi K,
Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B and
Montesa-Pino Á: Darolutamide and survival in metastatic,
hormone-sensitive prostate cancer. N Engl J Med. 386:1132–1142.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fizazi K, Foulon S, Carles J, Roubaud G,
McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P,
et al: Abiraterone plus prednisone added to androgen deprivation
therapy and docetaxel in de novo metastatic castration-sensitive
prostate cancer (PEACE-1): A multicentre, open-label, randomised,
phase 3 study with a 2 × 2 factorial design. Lancet. 399:1695–1707.
2022. View Article : Google Scholar
|
|
8
|
Gandaglia G, Abdollah F, Schiffmann J,
Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A,
Trinh QD, et al: Distribution of metastatic sites in patients with
prostate cancer: A population-based analysis. Prostate. 74:210–216.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gurel B, Ali TZ, Montgomery EA, Begum S,
Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI
and De Marzo AM: NKX3.1 as a marker of prostatic origin in
metastatic tumors. Am J Surg Pathol. 34:1097–1105. 2010. View Article : Google Scholar
|
|
10
|
Sweeney CJ, Martin AJ, Stockler MR, Begbie
S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG and
Joshua AM: Testosterone suppression plus enzalutamide versus
testosterone suppression plus standard antiandrogen therapy for
metastatic hormone-sensitive prostate cancer (ENZAMET): An
international, open-label, randomised, phase 3 trial. Lancet Oncol.
24:323–334. 2023. View Article : Google Scholar
|
|
11
|
National Cancer Institute, . Common
Terminology Criteria for Adverse Events (CTCAE). 2017.
|
|
12
|
Jegu J, Tretarre B, Velten M, Guizard AV,
Danzon A, Buemi A, Colonna M, Kadi-Hanifi AM, Ganry O, Molinie F,
et al: Prostate cancer management and factors associated with
radical prostatectomy in France in 2001. Prog Urol. 20:56–64.
2010.(In French). View Article : Google Scholar
|
|
13
|
Halabi S, Kelly WK, Ma H, Zhou H, Solomon
NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, et
al: Meta-analysis evaluating the impact of site of metastasis on
overall survival in men with castration-resistant prostate cancer.
J Clin Oncol. 34:1652–1659. 2016. View Article : Google Scholar
|
|
14
|
Vaghefi H, Magi-Galluzzi C and Klein EA:
Local recurrence of prostate cancer in rectal submucosa after
transrectal needle biopsy and radical prostatectomy. Urology.
66:8812005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Venara A, Thibaudeau E, Lebdai S, Mucci S,
Ridereau-Zins C, Azzouzi R and Hamy A: Rectal metastasis of
prostate cancer: About a case. J Clin Med Res. 2:137–139.
2010.PubMed/NCBI
|
|
16
|
Morita T, Meguro N, Tomooka Y, Maeda O,
Saiki S, Kuroda M, Miki T, Usami M and Kotake T: Rectal metastasis
of prostatic cancer causing annular stricture: A case report.
Hinyokika Kiyo. 37:295–298. 1991.(In Japanese). PubMed/NCBI
|
|
17
|
Tunio MA, Agamy AM, Fenn N, Hanratty D and
Williams NW: An unusual delayed rectal metastasis from prostate
cancer masquerading as primary rectal cancer. Int J Surg Case Rep.
100:1077322022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nwankwo N, Mirrakhimov AE, Zdunek T and
Bucher N: Prostate adenocarcinoma with a rectal metastasis. BMJ
Case Rep. 2013:bcr20130095032013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abbas TO, Al-Naimi AR, Yakoob RA, Al-Bozom
IA and Alobaidly AM: Prostate cancer metastases to the rectum: A
case report. World J Surg Oncol. 9:562011. View Article : Google Scholar
|
|
20
|
Liu ZH, Li C, Kang L, Zhou ZY, Situ S and
Wang JP: Prostate cancer incorrectly diagnosed as a rectal tumor: A
case report. Oncol Lett. 9:2647–2650. 2015. View Article : Google Scholar
|
|
21
|
Dulskas A, Cereska V, Zurauskas E,
Stratilatovas E and Jankevicius F: Prostate cancer solitary
metastasis to anal canal: Case report and review of literature. BMC
Cancer. 19:3742019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR and Humphrey PA; Grading Committee, : The 2014
International Society of Urological Pathology (ISUP) consensus
conference on gleason grading of prostatic carcinoma: Definition of
grading patterns and proposal for a new grading system. Am J Surg
Pathol. 40:244–252. 2016. View Article : Google Scholar
|
|
23
|
Swami U, Nazari S, Gebrael G, Elliott A,
Bagrodia A, Puri D, Nabhan C, McKay RR, Antonarakis ES and Agarwal
N: Differences in genomic, transcriptomic, and immune landscape of
prostate cancer (PCa) based on site of metastasis (mets). J Clin
Oncol. 42:212024. View Article : Google Scholar
|
|
24
|
Attard G, Murphy L, Clarke NW, Cross W,
Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, et
al: Abiraterone acetate and prednisolone with or without
enzalutamide for high-risk non-metastatic prostate cancer: A
meta-analysis of primary results from two randomised controlled
phase 3 trials of the STAMPEDE platform protocol. Lancet.
399:447–460. 2022. View Article : Google Scholar
|
